NightHawk Biosciences（纽约证券交易所代码：NHWK）股票跌破200日移动平均线1.26美元

NightHawk Biosciences, Inc. (NYSE:NHWK – Get Rating) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.26 and traded as low as $0.83. NightHawk Biosciences shares last traded at $0.84, with a volume of 45,612 shares traded.

NightHawk Biosciences Stock Performance

The stock has a market cap of $21.55 million, a P/E ratio of -0.47 and a beta of 0.57. The business has a 50 day moving average price of $1.00 and a 200 day moving average price of $1.26. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.08.

Institutional Trading of NightHawk Biosciences

A number of large investors have recently modified their holdings of NHWK. Vanguard Group Inc. purchased a new stake in NightHawk Biosciences during the third quarter worth $1,898,000. BlackRock Inc. purchased a new stake in NightHawk Biosciences during the third quarter worth $802,000. State Street Corp purchased a new stake in NightHawk Biosciences during the third quarter worth $178,000. Dimensional Fund Advisors LP purchased a new stake in NightHawk Biosciences during the third quarter worth $160,000. Finally, Millennium Management LLC purchased a new stake in NightHawk Biosciences during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 9.52% of the company's stock.

NightHawk Biosciences Company Profile

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Stories

• Get a free copy of the StockNews.com research report on NightHawk Biosciences (NHWK)
• Dave & Buster's Rebound Could Score for Investors
• Cal-Maine: Is it Time to Chase this Stock Higher?
• The Most Important Warren Buffett Stock for Investors: His Own
• Three Mid Caps Wall Street Sees Doubling Within 12 Months
• It's No Stretch: Lululemon Could Break Out of its Range

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.